Literature DB >> 21531994

Live birth chances in women with extremely low-serum anti-Mullerian hormone levels.

Andrea Weghofer1, Wolf Dietrich, David H Barad, Norbert Gleicher.   

Abstract

BACKGROUND: To determine whether women with extremely low-serum anti-Mullerian hormone (AMH) levels (<0.1-0.4 ng/ml) still demonstrate live birth potential with assisted reproduction and whether such potential is age dependent.
METHODS: Between January 2006 and October 2009, 128 consecutive infertility patients with AMH ≤0.4 ng/ml were retrospectively evaluated for pregnancy chances and live birth rates after IVF.
RESULTS: Patients presented at a mean (±SD) age of 40.8 ± 4.1 years, with mean (±SD) baseline FSH of 15.7 ± 11.1 mIU/ml and mean (±SD) AMH of 0.2 ± 0.1 ng/ml. One hundred and twenty-eight women underwent a total of 254 IVF cycles. Twenty clinical pregnancies were recorded (7.9% per cycle start [95% confidence interval (CI): 4.9-11.9%]; 15.6% cumulative [CI: 9.8-23.1%]). These pregnancies resulted in 13 live births in 12 women (i.e. 11 singletons and a pair of twins) and 8 patients miscarried. Eight deliveries occurred after the first cycle (6.3% per cycle start) and four after subsequent IVF cycles (3.2%). When evaluated according to female age, 70 women ≤42 years presented with 16 clinical pregnancies that resulted in 10 deliveries (14.3%), while 58 patients >42 years presented with four clinical pregnancies that resulted in 2 deliveries (3.4%), representing a reduced pregnancy chance (P = 0.013) and delivery rate (P = 0.036) versus age ≤42 years.
CONCLUSIONS: With extremely low-serum AMH levels, moderate, but reasonable pregnancy and live birth rates are still possible. Extremely low AMH levels do not seem to represent an appropriate marker for withholding fertility treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531994     DOI: 10.1093/humrep/der134

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  18 in total

1.  Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti-Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology.

Authors:  Iro Karagiorga; George A Partsinevelos; Despina Mavrogianni; Elli Anagnostou; Ioannis Zervomanolakis; Konstantinos Kallianidis; Petros Drakakis; Dimitris Loutradis
Journal:  J Assist Reprod Genet       Date:  2014-12-27       Impact factor: 3.412

2.  IVF results in patients with very low serum AMH are significantly affected by chronological age.

Authors:  Alberto Revelli; Valentina Biasoni; Gianluca Gennarelli; Stefano Canosa; Paola Dalmasso; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2016-02-18       Impact factor: 3.412

3.  The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment.

Authors:  Yoko Tokura; Osamu Yoshino; Sayaka Ogura-Nose; Hiroshi Motoyama; Miyuki Harada; Yutaka Osuga; Yasushi Shimizu; Motohiro Ohara; Takeshi Yorimitsu; Osamu Nishii; Shiro Kozuma; Toshihiro Kawamura
Journal:  J Assist Reprod Genet       Date:  2013-05-03       Impact factor: 3.412

4.  External validation of anti-Müllerian hormone based prediction of live birth in assisted conception.

Authors:  Amani Khader; Suzanne M Lloyd; Alex McConnachie; Richard Fleming; Valentina Grisendi; Antonio La Marca; Scott M Nelson
Journal:  J Ovarian Res       Date:  2013-01-07       Impact factor: 4.234

Review 5.  The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2011-08-17       Impact factor: 5.211

6.  Circulating LH/hCG receptor (LHCGR) may identify pre-treatment IVF patients at risk of OHSS and poor implantation.

Authors:  Anne E Chambers; Krishnaveni P Nayini; Walter E Mills; Gillian M Lockwood; Subhasis Banerjee
Journal:  Reprod Biol Endocrinol       Date:  2011-12-23       Impact factor: 5.211

7.  Follicle stimulating hormone and anti-Müllerian hormone per oocyte in predicting in vitro fertilization pregnancy in high responders: a cohort study.

Authors:  Andrea Weghofer; Ann Kim; David H Barad; Norbert Gleicher
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  Prospectively assessing risk for premature ovarian senescence in young females: a new paradigm.

Authors:  Norbert Gleicher; Vitaly A Kushnir; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2015-04-18       Impact factor: 5.211

9.  Poor responders: Is it time to consider changing the nomenclature?

Authors:  Priya Bhave Chittawar; Sachin Chittawar
Journal:  J Midlife Health       Date:  2012-07

10.  The IVF Outcome Counseling Based on the Model Combining DHEAS and Age in Patients with Low AMH Prior to the First Cycle of GnRH Antagonist Protocol of Ovarian Stimulation.

Authors:  Miro Šimun Alebić; Nataša Stojanović; Marta Zuvić-Butorac
Journal:  Int J Endocrinol       Date:  2013-02-24       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.